Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: Metadata lists "REVVITY, INC." but the filing text identifies the registrant as PerkinElmer, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 2, 2006
Business Overview: A leading provider of scientific instruments, consumables, and services to pharmaceutical, biomedical, academic research, and environmental markets. Operations are divided into two segments: Life and Analytical Sciences and Optoelectronics.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Sales (Revenue) | $355.5 million | $358.2 million |
| Gross Margin | 39.9% | 41.4% |
| Operating Income (Continuing Ops) | $29.0 million | $28.7 million |
| Net Income | $23.6 million | $19.8 million |
| Diluted EPS | $0.18 | $0.15 |
| Cash and Equivalents | $321.8 million | $184.2 million (End of Q1 2005) |
| Long-Term Debt | $206.6 million | $243.3 million (Jan 1, 2006) |
| Operating Cash Flow | ($34.7) million (Used) | $13.5 million (Provided) |
Material Changes vs. Prior Period
- Revenue: Sales decreased 1% ($2.7 million) year-over-year. The decline was driven by a $9.6 million negative impact from foreign exchange rates, partially offset by $1.4 million from acquisitions.
- Profitability: Net income increased 19% to $23.6 million. This improvement was largely due to a $2.0 million net gain on the disposition of discontinued operations (Semiconductor business) and a significant reduction in interest expense.
- Margins: Gross margin decreased 150 basis points to 39.9%, primarily due to capacity issues in the Optoelectronics amorphous silicon facility and unfavorable foreign exchange rates.
- Cash Flow: Operating cash flow turned negative ($34.7 million used) compared to positive cash flow in the prior year. This was primarily due to a $54.6 million tax payment related to divestitures and working capital changes.
- Capital Allocation: The company repurchased 5.0 million shares of common stock for $116.4 million and paid $9.1 million in dividends.
Guidance, Outlook, and Risks
- Accounting Changes: The company adopted SFAS No. 123(R) effective January 2, 2006, resulting in an incremental stock-based compensation expense of $1.7 million for the quarter.
- Strategic Moves: Completed the sale of the Fluid Sciences Semiconductor business (gain of $3.5 million) and acquired assets of Agilix Corporation ($8.7 million) and Spectral Genomics, Inc. ($12 million) to bolster the Life and Analytical Sciences segment.
- Restructuring: Continuing execution of Q4 2005 and Q2 2005 restructuring plans involving headcount reductions and facility closures. Remaining liabilities for these plans are approximately $2.8 million.
- Legal Contingencies: Ongoing patent litigation with Enzo Biochem and Amersham Biosciences. While the company won a ruling in the UK regarding Amersham's patent invalidity, Amersham has appealed. The company cannot estimate potential losses but believes it has meritorious defenses.
- Market Risks: Significant exposure to foreign exchange rate fluctuations and interest rate changes on variable-rate debt.
Investor Verification Checklist
- Divestiture Proceeds: Verify the final net working capital adjustments and contingent consideration related to the Fluid Sciences Semiconductor sale.
- Optoelectronics Capacity: Monitor the resolution of capacity issues at the amorphous silicon manufacturing facility impacting gross margins.
- Legal Outcomes: Track the status of the Amersham UK appeal and the NJ/MA patent litigation cases.
- Debt Covenants: Confirm continued compliance with the interest coverage and debt-to-EBITDA ratios under the new $350 million senior unsecured credit facility.
- Stock Repurchase: Note that approximately 3.9 million shares remain available under the current repurchase program authorization.